Ledger.Open graph →
SEC Form D · filed July 10, 2024

Checkpoint Therapeutics, Inc

Offering
—
Sold
—
Exemption
Rule 506(b)
Industry
Biotechnology
Location
WALTHAM, MA
Type
—

Rule 506(b): private placement to accredited investors, no public advertising.

People & firms on this filing (23)

Jose M. Moran Adarraga · Madrid, U3DirectorAmit A. Sharma · Waltham, MADirectorHiroaki Kobayashi · BALTIMORE, MDDirectorAshley Mayer · Dover, DEDirectorMichael F. Weiss · Waltham, MADirectorAkihiro Ko · BALTIMORE, MDDirectorToyin Ajayi · Dover, DEDirectorManuel E. Tarrasa Sanchez · Madrid, U3DirectorBarry F. Salzman · Waltham, MADirectorBarbara Serrano Sanchez · Madrid, U3DirectorMarco M. Buhigas Moran · Madrid, U3Exec · DirectorThomas P. Railhac · London, United KingdomDirectorJames F. Oliviero, Iii · Waltham, MAExec · DirectorJeffrey Cleland · BALTIMORE, MDDirectorDavid Carew · Toronto, Ontario, CanadaExec · DirectorNeil F. Herskowitz · Waltham, MADirectorSven Gosta P. Pattersson · London, United KingdomDirectorAmit A. Sharma · Waltham, MADirectorStuart Orgill · San Francisco, CAExecLindsay A. Rosenwald · Waltham, MADirectorChristian F. Bechon · Waltham, MADirectorGarrett F. Gray · Waltham, MAExecMaxim D. Crewe · London, United KingdomExec

Public SEC Form D (Reg D) filing. · View issuer on SEC EDGAR ↗